YN340002 EAI045 1942114-09-1

EAI045 is an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.

YN340061 MTX-211 1952236-05-3

MTX-211 is a first-in-class dual inhibitor of PI3K and EGFR kinase .

YN340116 Mutated EGFR-IN-2 2050906-97-1

Mutated EGFR-IN-2 (compound 91) is a mutant-selectiveEGFRinhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC50=...

YN340248 Osimertinib dimesylate 2070014-82-1

Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selectiveEGFRinhibitor with IC50s of 12 and 1nM against EGFRL858R and EGFRL858R/T790M, respectively.

YN340063 Epertinib hydrochloride 2071195-74-7

Epertinib hydrochloride (S-22611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor ofEGFR,HER2 and HER4, with IC50s of 1.48nM, 7.15nM and 2.49nM, respectively. Epertinib hyd...

YN340073 TAS0728 2088323-16-2

TAS0728 is a potent, selective, orally active, irreversible and covalent-bindingHER2inhibitor, binds to HER2 at C805, inhibits its kinase activity, with an IC50 of 13nM. TAS0728 shows IC50s of 4.9, 8.5, 31, 65, 33, 25, 8...

YN340100 CCT365623 hydrochloride 2126136-98-7

CCT365623 hydrochloride is an orally activelysyl oxidase (LOX)inhibitor, with an IC50 of 0.89μM. CCT365623 hydrochloride suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 hydrochloride is...

YN340083 AST2818 mesylate 2130958-55-1

AST2818 mesylate is anEGFRinhibitor.

YN340082 Almonertinib hydrochloride 2134096-03-8

Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generationEGFR tyrosine kinaseinhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib hydrochloride ...

YN340234 Tarlox-TKI 2135696-72-7

Tarlox-TKI, the active metabolite of Tarloxotinib, is an irreversible pan-ErbBTKI (Tarlox-TKI).

YN340139 (Rac)-JBJ-04-125-02 2140807-05-0

(Rac)-JBJ-04-125-02 (JBJ-04-125-02 racemate) is a mutant-selective allosteric inhibitor of Epidermal growth factor receptor (EGFR) with potential anticancer activity.

YN340072 EGFR-IN-5 2225887-26-1

EGFR-IN-5 is aEGFRinhibitor with IC50s of 10.4, 1.1, 34, 7.2nM for EGFR, EGFRL858R, EGFRL858R/T790M, and EGFRL858R/T790M/C797S, respectively.

YN340070 PKI-166 hydrochloride 2230253-82-2

PKI-166 hydrochloride is a potent, selective and orally bioavailableEGFR tyrosine kinaseinhibitor, with an IC50 of 0.7nM.

YN340098 Gefitinib-based PROTAC ... 2230821-27-7

Gefitinib-based PROTAC 3, conjugating an EGFR binding element to a VHL lig and via a linker, inducesEGFRdegradation withDC50s of 11.7nM and 22.3nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, re...

YN340088 JND3229 2260886-64-2

JND3229 is a highly potent and fourth-generation EGFRC797Sreversible inhibitor with IC50 value of 5.8nM, and also potently suppressed EGFRL858R/T790M and EGFRWTwith IC50 values of 30.5 and 6.8nM.

YN340117 EGFR-IN-7 2267329-76-8

EGFR-IN-7 (compound 34) is a selective and potentEGFR kinaseinhibitor extracted from patent WO2019015655A1, hasIC50s of 7.92nM and 0.218nM for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) respectively...

YN340144 JCN037 2305154-31-6

JCN037 (JGK037) is non-covalent and BBB-penetrantEGFRtyrosine kinase inhibitor, with IC50 values of 2.49nM, 3.95nM, 4.48nM for EGFR, p-wtEGFR and pEGFRvⅢ, respectively.

YN340254 AZ7550 hydrochloride 2309762-40-9

AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity ofIGF1Rwith an IC50 of 1.6μM.

YN340141 Mobocertinib succinate 2389149-74-8

Mobocertinib succinate (TAK-788 succinate) is a potent and orally active inhibitor ofEGFR and HER2oncogenic mutants, including exon 20 insertions, with selectivity over WT EGFR. Antitumor activity.

YN340109 EGFR-IN-8 2407957-87-1

EGFR-IN-8 is a dualEGFR and c-Metinhibitor, compound 48. EGFR-IN-8 can be a promising c and idate for further development to target EGFR TKI-resistant NSCLC.